Role of Calcium Channel Blockers in Myocardial Preconditioning

1. Piper HM, Garcia-Dorado D, Ovize M. A fresh look at reperfusion injury. Cardiovasc Res. 1998;38(2):291-300.10.1016/S0008-6363(98)00033-9Open DOISearch in Google Scholar

2. Vinod NK, Rupinder SM, Murugesan C. Myocardial ischaemic preconditioning. Indian Journal of Anaesthesia. 2004;48:93.Search in Google Scholar

3. Duan HF, Wu CT, Wu DL, et al. Treatment of myocardial ischemia with bone marrow-derived mesenchymal stem cells overexpressing hepatocyte growth factor. Molecular therapy. 2003;8(3):467-74.10.1016/S1525-0016(03)00186-2Open DOISearch in Google Scholar

4. Przyklenk K, Kloner RA. Ischemic preconditioning: exploring the paradox. Progress in cardiovascular diseases. 1998;40:517-47.10.1016/S0033-0620(98)80002-9Search in Google Scholar

5. Alserius T, Hammar N, Nordqvist T, Ivert T. Risk of death or acute myocardial infarction 10 years after coronary artery bypass surgery in relation to type of diabetes. Am Heart J. 2006;152(3):599-605.10.1016/j.ahj.2006.02.010Search in Google Scholar

6. Cutrn JC, Perrelli MG, Cavalieri B, Peralta C, Rosell Catafau J, Poli J. Microvascular dysfunction induced by reperfusion injury and protective effect of ischemic preconditioning. Free Radic Biol Med. 2002;33(9):1200-8.10.1016/S0891-5849(02)01017-1Search in Google Scholar

7. Janoff A. Alterations in lysosomes (intracellular enzymes) during shock; effects of preconditioning (tolerance) and protective drugs. International anesthesiology clinics. 1964;2(2):251-70.10.1097/00004311-196402000-00008Open DOISearch in Google Scholar

8. Muller DWM, Topol EJ, Califf RM, Sigmon KN, Gorman L. Relationship between antecedent angina pectoris and short term prognosis after thrombolytic therapy for acute myocardial infarction. Am Heart J. 1990;119:224-31.10.1016/S0002-8703(05)80008-0Search in Google Scholar

9. Pomerantz BJ, Joo K, Shames BD, Cleveland JC Jr, Banerjee A, Harken AH. Adenosine preconditioning reduces both pre and postischemic arrhythmias in human myocardium. J Surg Res. 2000;90(2):191-6.10.1006/jsre.2000.588910792962Open DOISearch in Google Scholar

10. Luh SP, Yang PC. Organ preconditioning: the past, current status, and related lung studies. J Zhejiang Univ Sci B. 2006;7(5):331-41.10.1631/jzus.2006.B0331146293316615162Search in Google Scholar

11. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986;74:1124-36.10.1161/01.CIR.74.5.11243769170Search in Google Scholar

12. Liu Y, Downey JM. Ischemic preconditioning protects against infarction in rat heart. Am J Physiol. 1992;263:H1107-12.10.1152/ajpheart.1992.263.4.H11071415759Search in Google Scholar

13. Liu GS, Thornton J, Van Winkle DM, et al. Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart. Circulation. 1991;84:350-6.10.1161/01.CIR.84.1.350Search in Google Scholar

14. Schott RJ, Rohmann S, Braun ER, et al. Ischemic preconditioning reduces infarct size in swine myocardium. Circ Res. 1990;66:1133-42.10.1161/01.RES.66.4.11332317890Search in Google Scholar

15. Kloner Ra, Shook T, Przyklenk K, et al. Previous angina alters in-hospital outcome in TIMI 4: a clinical correlate to preconditioning? Circulation. 1995;91:37-45.10.1161/01.CIR.91.1.37Open DOISearch in Google Scholar

16. Sanada S, Komuro I, Kitakaze M. Pathophysiology of myocardial reperfusion injury: preconditioning, postconditioning, and translational aspects of protective measures. Am J Physiol Heart Circ Physiol. 2011;301(5):1723-41.10.1152/ajpheart.00553.201121856909Search in Google Scholar

17. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med. 2007;357(11):1121-3510.1056/NEJMra07166717855673Search in Google Scholar

18. Iliodromitis EK, Lazou A, Kremastinos DT. Ischemic preconditioning: protection against myocardial necrosis and apoptosis. Vasc Health Risk Manag. 2007;3(5):629-37.Search in Google Scholar

19. Speechly-Dick ME, Mocanu MM, Yellon DM. Protein kinase C: its role in ischemic preconditioning in the rat. Circ Res. 1994;75:586-90.10.1161/01.RES.75.3.5868062429Open DOISearch in Google Scholar

20. Steenbergen C, Fralix TA, Murphy E. Role of increased cytosolic free calcium concentration in myocardial ischemic injury. Basic Res Cardiol 1993;88:456-70.10.1007/BF007954128117251Open DOISearch in Google Scholar

21. Silverman HS, Stern MD. Ionic basis of ischaemic cardiac injury: insights from cellular studies. Cardiovasc Res 1994;28:581-97.10.1093/cvr/28.5.5818025901Open DOISearch in Google Scholar

22. Liu Y, Sato T, O’Rourke B, Marban E. Mitochondrial ATP-dependent potassium channels: novel effectors of cardioprotection? Circulation. 1998;97(24):2463-9.10.1161/01.CIR.97.24.2463Open DOISearch in Google Scholar

23. Crossman DC. The pathophysiology of myocardial ischaemia. Heart. 2004;90(5):576-80.10.1136/hrt.2003.029017176824115084567Open DOISearch in Google Scholar

24. Jones CJ, Kuo L, Davis MJ, et al. Role of nitric oxide in the coronary microvascular responses to adenosine and increased metabolic demand. Circulation. 1995;91:1807-13.10.1161/01.CIR.91.6.1807Search in Google Scholar

25. Meldrum DR. Mechanisms of cardiac preconditioning: ten years after the discovery of ischemic preconditioning. J Surg Res. 1997;73(1):1-13.10.1006/jsre.1997.51879441786Search in Google Scholar

26. Hausenloy DJ, Yellon DM. Myocardial ischemia-reperfusion injury: a neglected therapeutic target. J Clin Invest. 2013;123(1):92-100.10.1172/JCI62874353327523281415Search in Google Scholar

27. Jennings RB, Reimer KA. The cell biology of acute myocardial ischemia. Annu Rev Med. 1991;42:225-46.10.1146/annurev.me.42.020191.0013012035969Open DOISearch in Google Scholar

28. Verma S, Fedak PW, Weisel RD, et al. Fundamentals of reperfusion injury for the clinical cardiologist. Circulation. 2002;105(20):2332-6.10.1161/01.CIR.0000016602.96363.3612021216Search in Google Scholar

29. Mittal D, Taliyan R, Sharma PL, Yadav HN. Effect of pioglitazone on the abrogated cardioprotective effect of ischemic preconditioning in hyperlipidemic rat heart. Indian J Pharmacol. 2016;48(1):59-63.10.4103/0253-7613.174545477820926997724Search in Google Scholar

30. Dorsch M, Behmenburg F, Raible M, et al. Morphine-Induced Preconditioning: Involvement of Protein Kinase A and Mitochondrial Permeability Transition Pore. PLoS One. 2016;11(3):e0151025.10.1371/journal.pone.0151025478845126968004Search in Google Scholar

31. Müllenheim J, Ebel D, Frässdorf J, Preckel B, Thämer V, Schlack W. Isoflurane preconditions myocardium against infarction via release of free radicals. Anesthesiology. 2002;96(4):934–40.10.1097/00000542-200204000-0002211964602Open DOISearch in Google Scholar

32. Jeremic N, Petkovic A, Srejovic I, Zivkovic V, Djuric D, Jakovljevic V. Effects of ischemia and omeprazole preconditioning on functional recovery of isolated rat heart. Rev Bras Cir Cardiovasc. 2015;30(2):266-75.10.5935/1678-9741.20150020446297426107460Search in Google Scholar

33. Miyawaki H, Ashraf M. Ca²⁺ as a mediator of ischemic preconditioning. Circ Res. 1997;80: 790-9.10.1161/01.RES.80.6.790Open DOISearch in Google Scholar

34. Smith GB, Stefenelli T, Wu ST, Wilkman-Coffelt J, Parmley WW, Zaugg CE. Rapid adaptation of myocardial calcium homeostasis to short episodes of ischemia in isolated rat hearts. Am Heart J. 1996;131:1106-1112.10.1016/S0002-8703(96)90084-8Search in Google Scholar

35. Dagenais F, Cartier R, Hollmann C, Buluran J. Calcium-channel blockers preserve coronary endothelial reactivity after ischemia-reperfusion. Ann Thorac Surg. 1997;63:1050-6.10.1016/S0003-4975(96)01278-7Open DOISearch in Google Scholar

36. Hugtenburg JG, Van Voorst MJ, Van Marle J, et al. The influence of nifedipine and mioflazine on mitochondrial calcium overload in normoxic and ischaemic guinea-pig hearts. Eur J Pharmacol. 1990;178:71-8.10.1016/0014-2999(90)94794-XSearch in Google Scholar

37. Braunwald E. Mechanism of action of calcium-channel-blocking agents. New England Journal of Medicine. 1982; 307(26):1618-27.10.1056/NEJM198212233072605Search in Google Scholar

38. Brichard G, Zimmermann PE. Verapamil in cardiac dysrhythmias during anesthesia. British Journal of anesthesia. 1970;42(11):1005-12.10.1093/bja/42.11.1005Search in Google Scholar

39. Freher M, Challapalli S, Pinto JV, Schwartz J, Bonow RO, Gheorgiade M. Current status of calcium channel blockers in patients with cardiovascular disease. Curr Probl Cardiol. 1999;24:236-40.10.1016/S0146-2806(99)90000-2Search in Google Scholar

40. Weir MR. Calcium channel blockers: differences between subclasses. Am J Cardiovasc Drugs. 2007;7:5-15.Search in Google Scholar

41. Frishman W.H. Calcium channel blockers: differences between subclasses. Am J Cardiovasc Drugs. 2007;7:17-23.Search in Google Scholar

42. Hofmann F, Lacinova L, Klugbauer N. Voltage-dependent calcium channels: From structure to function. Rev Physiol Biochem Pharmacol. 1999;139:33-87.10.1007/BFb0033648Search in Google Scholar

43. Cleophas TJ, van Marun R. Meta-analysis of efficacy and safety of second-generation dihydropyridine calcium channel blockers in heart failure. Am J Cardiol. 2001;87:487-90.10.1016/S0002-9149(00)01413-2Search in Google Scholar

44. Ruzicka M, Leenen FH. Relevance of 24 H blood pressure profile and sympathetic activity for outcome on short-versus long-acting 1,4-dihydropyridines. Am J Hypertens. 1996;9:86-94.10.1016/0895-7061(95)00350-9Search in Google Scholar

45. Millar JA, McLean KA, Sumner DJ, et al. The effect of the calcium antagonist nifedipine on pressor and aldosterone responses to angiotensin II in normal man. Eur J Clin Pharmacol. 1983;24:315-21.10.1007/BF00610047Open DOISearch in Google Scholar

46. Krishna GG, Riley LJ, Deuter G, et al. Natriuretic effect of calcium-channel blockers in hypertensives. Am J Kidney Dis. 1991;18:566-72.10.1016/S0272-6386(12)80651-2Open DOISearch in Google Scholar

47. Cutler JA. Calcium-channel blocker for hypertension-uncertainty continues. N Engl J Med. 1998; 338:679-81.10.1056/NEJM199803053381009Search in Google Scholar

48. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA. 1995;274:620-5.10.1001/jama.1995.03530080036038Search in Google Scholar

49. Shen AC, Jennings RB. Myocardial calcium and magnesium in acute ischemic injury. Am J Pathol. 1972;67(3):417-40.Search in Google Scholar

50. Kiowski W, Buhler FR, Fadayomi MO, et al. Age, race, blood pressure and renin: predictors for antihypertensive treatment with calcium antagonists. Am J Cardiol. 1985;56:81-5.10.1016/0002-9149(85)90549-1Search in Google Scholar

51. Sica DA. Pharmacotherapy review: calcium channel blockers. J Clin Hypertens (Greenwich). 2006;8(1):53-6.10.1111/j.1524-6175.2005.04140.x810962516407690Search in Google Scholar

52. Curt FD, Psaty MB, Meyer VJ. Nifedipine dose-related increase in mortality in patients with coronary heart disease. Circulation. 1995;92:1326-31.10.1161/01.CIR.92.5.13267648682Search in Google Scholar

53. Waters D. Proischemic complications of dihydropyridine calcium channel blockers. Circulation. 1991;84:2598-2600.10.1161/01.CIR.84.6.2598Search in Google Scholar

54. Cain BS, Meldrum DR, Cleveland JC Jr, Meng X, Banerjee A, Harken AH. Clinical L-type Ca(2+) channel blockade prevents ischemic preconditioning of human myocardium. J Mol Cell Cardiol. 1999;31(12):2191-7.10.1006/jmcc.1999.103910640446Open DOISearch in Google Scholar

55. Wallbridge DR, Schulz R, Braun C, Post H, Heusch G. No attenuation of ischaemic preconditioning by the calcium antagonist nisoldipine. J Mol Cell Cardiol. 1996;28(8):1801-10.10.1006/jmcc.1996.01698877789Search in Google Scholar

56. Camara AK, Chen Q, Rhodes SS, Riess ML, Stowe DF. Negative inotropic drugs alter indexes of cytosolic [Ca(²⁺)]-left ventricular pressure relationships afterischemia. Am J Physiol Heart Circ Physiol. 2004;287(2):H667-80.10.1152/ajpheart.01142.2003Search in Google Scholar

57. Dilmac N, Hilliard N, Hockerman GH: Molecular determinants of frequency dependence and Ca²⁺ potentiation of verapamil block in the pore region of Cav1.2. Mol Pharmacol. 2004;66(5):1236-47.10.1124/mol.104.000893Open DOISearch in Google Scholar

58. Miyawaki H, Zhou X, Ashraf M. Calcium preconditioning elicits strong protection against ischemic injury via protein kinase C signaling pathway. Circ Res. 1996;79:137-146.10.1161/01.RES.79.1.137Open DOISearch in Google Scholar

59. Henry PD. Comparative pharmacology of calcium antagonists: nifedipine, verapamil and diltiazem. The American journal of cardiology. 1980;46(6):1047-58.10.1016/0002-9149(80)90366-5Search in Google Scholar

60. Yu W, Wang JJ, Gan WY, Lin GS, Huang CX. Effects of verapamil preconditioning on cardiac function in vitro and intracellular free Ca2+ and L-type calcium current in rat cardiomyocytes post ischemia-reperfusion injury. Zhonghua Xin Xue Guan Bing Za Zhi. 2010;38(3):225-9.Search in Google Scholar

61. Okuda K, Nohara R, Ogino M, et al. Limitation of infarct size with preconditioning and calcium antagonist (Diltiazem): Difference in ⁹⁹mTc-PYP uptake in the myocardium. Annals of nuclear medicine. 1996;10(2):201-9.10.1007/BF03165393Search in Google Scholar

62. De Jong JW, Harmsen E, De Tombe PP. Diltiazem administered before or during myocardial ischemia decreases adenine nucleotide catabolism. J Mol Cell Cardiol. 1984;16(4):363-70.10.1016/S0022-2828(84)80607-0Open DOISearch in Google Scholar

63. Taira N. Nicorandil as a hybrid between nitrates and potassium channel activators. Am J Cardiol. 1989;63:18J-24J.10.1016/0002-9149(89)90200-2Search in Google Scholar

64. The IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the impact of nicorandil in angina (IONA) randomized trial. Lancet 2002;359:1269–75.10.1016/S0140-6736(02)08265-XSearch in Google Scholar

65. Lablanche JM, Bauters C, Leroy F et al. Prevention of coronary spasm by nicorandil: Comparison with nifedipine. J Cardiovasc Pharmacol. 1992;20:S82–5.10.1097/00005344-199206203-00014Search in Google Scholar

66. Ohno Y, Minatoguchi S, Uno Y, Kariya T, Arai M, Yamashita K, Fujiwara T, Fujiwara H. Nicorandil reduces myocardial infarct size by opening the K(ATP) channel in rabbits. Int J Cardiol. 1997;62(3):181-90.10.1016/S0167-5273(97)00270-2Open DOISearch in Google Scholar

67. Matsubara T, Minatoguchi S, Matsuo H, et al. Three minute, but not one minute, ischemia and nicorandil have a preconditioning effect in patients with coronary artery disease. J Am Coll Cardiol. 2000;35(2):345-51.10.1016/S0735-1097(99)00539-2Open DOISearch in Google Scholar

68. Tang XL, Xuan YT, Zhu Y, Shirk G, Bolli R. Nicorandil induces late preconditioning against myocardial infarction in conscious rabbits. Am J Physiol Heart Circ Physiol. 2004;286(4):H1273-80.10.1152/ajpheart.01055.2003Search in Google Scholar

69. Ahmed LA, Salem HA, Attia AS, Agha AM. Pharmacological preconditioning with nicorandil and pioglitazone attenuates myocardial ischemia/reperfusion injury in rats. Eur J Pharmacol. 2011;663(1-3):51-8.10.1016/j.ejphar.2011.04.038Search in Google Scholar

70. Rajesh KG, Sasaguri S, Zhitian Z, Suzuki R, Asakai R, Maeda H. Second window of ischemic preconditioning regulates mitochondrial permeability transition pore by enhancing Bcl-2 expression. Cardiovasc Res. 2003;59(2):297-307.10.1016/S0008-6363(03)00358-4Search in Google Scholar

71. Matsuo H, Watanabe S, Segawa T, et al. Evidence of pharmacologic preconditioning during PTCA by intravenous pretreatment with ATP-sensitive K+ channel opener nicorandil. Eur Heart J. 2003;24(14):1296-303.10.1016/S0195-668X(03)00202-1Search in Google Scholar

72. Sakai K, Yamagata T, Teragawa H, Matsuura H, Chayama K. Nicorandil enhances myocardial tolerance to ischemia without progressive collateral recruitment during coronary angioplasty. Circulation journal. 2002;66(4):317-22.10.1253/circj.66.317Open DOISearch in Google Scholar

73. Kitakaze M, Asakura M, Kim J, et al. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): 2 randomised trials. Lancet. 2007;370(9597):1483-93.10.1016/S0140-6736(07)61634-1Search in Google Scholar